Literature DB >> 4146209

Norphenazone, a new metabolite of phenazone in human urine.

J D Baty, D A Evans.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4146209     DOI: 10.1111/j.2042-7158.1973.tb09124.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


× No keyword cloud information.
  14 in total

1.  Disposition of antipyrine in patients with extensive metastatic liver disease.

Authors:  G M Robertz-Vaupel; K D Lindecken; T Edeki; C Funke; S Belwon; H J Dengler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 2.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

3.  Gas chromatographic assessment of the reproducibility of phenazone plasma half-life in young healthy volunteers.

Authors:  S Lindgren; P Collste; B Norlander; F Sjöqvist
Journal:  Eur J Clin Pharmacol       Date:  1974-08-23       Impact factor: 2.953

Review 4.  Assessment of the drug metabolism capacity of the liver.

Authors:  B K Park
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

5.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

6.  Monogenic control of variations in antipyrine metabolite formation. New polymorphism of hepatic drug oxidation.

Authors:  M B Penno; E S Vesell
Journal:  J Clin Invest       Date:  1983-06       Impact factor: 14.808

7.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

8.  Studies of the different metabolic pathways of antipyrine in man. Oral versus i.v. administration and the influence of urinary collection time.

Authors:  M Danhof; A van Zuilen; J K Boeijinga; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

9.  Antipyrine metabolite formation in children in the acute phase of malnutrition and after recovery.

Authors:  N Buchanan; M Davis; M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1980-10       Impact factor: 4.335

10.  Tolbutamide as a model drug for the study of enzyme induction and enzyme inhibition in the rat.

Authors:  D J Back; F Sutcliffe; J F Tjia
Journal:  Br J Pharmacol       Date:  1984-03       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.